Dr Anthony Carmen Brutico, MD | |
940 Jefferson Ave, Scranton, PA 18510-1007 | |
(570) 346-7900 | |
(570) 963-5060 |
Full Name | Dr Anthony Carmen Brutico |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Experience | 44 Years |
Location | 940 Jefferson Ave, Scranton, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194725598 | NPI | - | NPPES |
0011941970002 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | MD025444E (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Wayne Memorial Hospital | Honesdale, PA | Hospital |
Geisinger-community Medical Center | Scranton, PA | Hospital |
Regional Hospital Of Scranton | Scranton, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Lehigh Valley Physician Group | 3072425123 | 1763 |
News Archive
Men are missing from fertility debates and crucial support services because they are often not included in studies and, when they are, it is usually only married, heterosexual men who are asked for data.
The risk of viral infections is known to be affected by physical activity, but little information is available regarding the more serious infections caused by bacteria.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.
BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.
› Verified 2 days ago
Entity Name | Lehigh Valley Physician Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
Men are missing from fertility debates and crucial support services because they are often not included in studies and, when they are, it is usually only married, heterosexual men who are asked for data.
The risk of viral infections is known to be affected by physical activity, but little information is available regarding the more serious infections caused by bacteria.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.
BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.
› Verified 2 days ago
Entity Name | Delta Medix Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1396701876 PECOS PAC ID: 0648162636 Enrollment ID: O20040325001062 |
News Archive
Men are missing from fertility debates and crucial support services because they are often not included in studies and, when they are, it is usually only married, heterosexual men who are asked for data.
The risk of viral infections is known to be affected by physical activity, but little information is available regarding the more serious infections caused by bacteria.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.
BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Anthony Carmen Brutico, MD Po Box 783311, Philadelphia, PA 19178-3311 Ph: (484) 884-4500 | Dr Anthony Carmen Brutico, MD 940 Jefferson Ave, Scranton, PA 18510-1007 Ph: (570) 346-7900 |
News Archive
Men are missing from fertility debates and crucial support services because they are often not included in studies and, when they are, it is usually only married, heterosexual men who are asked for data.
The risk of viral infections is known to be affected by physical activity, but little information is available regarding the more serious infections caused by bacteria.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.
BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.
› Verified 2 days ago
Dr. Keith Michael Pritchyk, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 300 Lackawanna Ave Ste 200, Scranton, PA 18503 Phone: 570-342-7864 Fax: 570-800-7515 | |
Dr. Mark Anthony Frattali, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 300 Lackawanna Ave Ste 200, Scranton, PA 18503 Phone: 570-342-7864 Fax: 570-840-1259 | |
John J Sirotnak Iii, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3 W Olive St, Scranton, PA 18508 Phone: 570-558-2100 Fax: 570-558-2101 | |
Dr. William Anthony Wood, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3 W Olive St, Scranton, PA 18508 Phone: 570-558-2100 Fax: 570-558-2101 |